102
in diseases of the airways: beyond
the antimicrobial effects. Pneumon
2013; 26 (1): 33 -46
59.
Feldman C, Anderson R. Non – an-
timicrobial activity of macrolides:
therapeutic potential in chronic in-
flammatory airway disordes. J Epi-
demiol Infect 2009; 24(4): 21- 26
60.
Richeldi L, Ferrrara G, Fabbri LM.
Lasserson TJ, Gibson PG. Mac-
rólides for chronic asthma, Rew-
iew. Cochrane Database Syst Rev,
2005; CD002997
61.
Koutsoubari I, Papaevangelou V,
Konstantinou GN, et al. Effect of
clarithromycin on acute asthma
exacerbations in children: an open
randomized study. Pediatr Allergy
Immunol 2012; 23: 385 - 392
62.
Piacentini GL, Peroni DG, Bodini A,
Pigozzi R, Costella S, Loiacano et al.
Azytromicin reduces bronchial hy-
per-responsiveness and neutrofilic
airway inflammation in asthmatic
children: A preliminary report. Aller-
gy Asthma Proc. 2007; 28: 194-8.
63.
Fonseca – Aten M, O, Kada PK,
BowlwareKL, Chavez-Bueno S, Me-
jias A, Rios AM, et al. Effect of clari-
thromycin on cytokines and chemo-
kines in children with an acute
exacerbation of recurrent wheezing:
a doublé-blind, randomized, pla-
cebo-controlled trial. Ann Allergy
Asthma Immunol 2006; 97: 457-63.
64.
Koretmasu S, YamamotoK, Tomoka-
zu N et al. The indication and effec-
tiveness of low- dose erythromycin
therapy in pediatric patients with
bronchial asthma. Pediatr Allergy
Immunol 2010: 21: 489 – 492
65.
Strunk RC, Bacherier LB, Phillips B,
Szefler S, Zeiger R, Chinchilli VM,
Martinez FD, et al. Azithromycin or
montelukast as inhaled corticoste-
roid – sparing agents in moderate
to severe childhood asthma study.
tion with a long-acting beta2-ago-
nist in asthmatic children under age
5. J Asthma 2004; 41: 575-582.
51.
Schwarzer G, Bassler D, Mitra A,
Ducharme F, Foster J. Ketotifen
alone or as additional medication
for long-term control of asthm and
wheeze in children. Cochrane Data-
base Syst Rev 2004; 1, CD 001384
52.
Warner JO. A double – blinded, ran-
domized, lcebo – controlled trial of
cetirizine in preventing the onset of
asthma in children with atopic der-
matitis: 18 months teratment and
18 months postreatment follow-up.
J Allergy Clin Immuno 2001 ; 108 :
929- 37
53.
74. Conway SP, Houlsby WT. Slow
release theophylline in preschool
asthmatics.
Arch Dis Child 1986; 61: 1024-1026.
54.
Mailing HJ, Weeke B. EEACI Positi-
on paper: Immunotherapy. Allergy
1993; 48 (14 suppl): 7-35
55.
BousquetJ, Van Cauwenberge P,
Khaltaev M, ARIA Workshp Group.
World Health Organization. Allergic
rhinitis and its impact on asthma. J
Allergy Clin Immunol 2001: 108 (5
suppl): S147 – S334.
56.
Rodriguez Perez N, Ambriz Moreno
Mde J. Safety of immunotherapy
and skin test with alergens in chil-
dren younger than five years.
Rev Alerg Mex 2006 53 ( 2 ): 47 -51
57.
Hernandez N, Ibero M, Ridao M, Ar-
tigas R, Viñas M, Castillo MJ. Safety
os specific immnutherapy using a
despigmented and polymerised ex-
tract of Dermatophagoides pteron-
yssinus in children under five years
of age. Allergol Immunopathol
2011; 39 (5): 267-70
58.
Kryfti M. Bartziokas K, Papaioan-
nou A. Papadopoulos A, Kostikas K.
Clinical effectiveness of macrolides
Niño con sibilancias recurrentes por debajo de los 3 años. Estrategias terapeúticas…
